Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Discovery Immunology|April 3, 2024
What do cancer-specific T cells 'see'?Sabaria Shah, Abdullah Al-Omari, Katherine W Cook, et al.
Oncotarget|November 9, 2016
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumorsWei Xue, Victoria A Brentville, Peter Symonds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancerTimothy J Duncan, Phil Rolland, Suha Deen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patientsGustave J Ullenhag, Abhik Mukherjee, Nicholas F S Watson, et al.
World Journal of Surgical Oncology|July 21, 2005
Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patientsNicholas F S Watson, Zahra Madjd, Duncan Scrimegour, et al.
Gut|June 29, 2010
Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancerJonathan A D Simpson, Ahmad Al-Attar, Nicholas F S Watson, et al.
BMC Cancer|November 13, 2012
Calpain system protein expression in carcinomas of the pancreas, bile duct and ampullaSarah J Storr, Abed M Zaitoun, Arvind Arora, et al.
Oncoimmunology|July 30, 2016
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockadeWei Xue, Rachael L Metheringham, Victoria A Brentville, et al.
International Journal of Cancer|July 9, 2005
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosisNicholas F S Watson, Judith M Ramage, Zahra Madjd, et al.
Cancer Immunology, Immunotherapy : CII|September 21, 2004
Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?Zahra Madjd, Lindy G Durrant, Sarah E Pinder, et al.
Pageof 8